Evaluation of efficacy and safety of Terbinafine, Fluconazole and Itraconazole in skin fungal infections
Phase 4
Completed
- Conditions
- Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
- Registration Number
- CTRI/2018/04/013303
- Lead Sponsor
- Dr D Aruna
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients aged between 18 - 60 years of either sex.
2. Patients freshly diagnosed
3. Patients willing to give written informed consent.
Exclusion Criteria
1. Patients hypersensitive to study drugs.
2. Pregnant and lactating women.
3. Patients having pre-existing renal, liver and cardiac illness.
4. Patients already on treatment with topical antifungal agents.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the clinical efficacy and mycological clearance, and patient’s compliance.Timepoint: 0 day,15 day, 30 day
- Secondary Outcome Measures
Name Time Method Adverse effects and cost-effectivenessTimepoint: 0 day,15 day, 30 day